Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
Visx and Icahn part ways: Prompted by rejection of nominee Keith Meister to Visx' board of directors, financier Carl Icahn sells approximately 6 mil. shares of firm's stock to Goldman Sachs, of which 3.5 mil. shares were repurchased by Visx. The sale of Icahn's stake in the company ends a tumultuous relationship that began in August 2000 between the firm's single largest shareholder and Chairman/CEO Liz Davilla. Visx stock closed at $17.35 on May 29, the day of the announcement. Icahn's most notable confrontation with Visx' board was a $32-per-share hostile takeover bid for the company in April 2001 (1"The Gray Sheet" April 28, 2003, p. 22)...
You may also be interested in...
Visx, Alcon Hope LASIK Market Will Get A Boost From Wavefront Technology
Visx plans to leverage its leadership position in LASIK system placements to market its custom wavefront-guided laser correction technology, which is expected to be approved by FDA this quarter
Medex’ Purchase Of J&J Vascular Access Expected To Close By June
Medex will leverage the brand recognition of Ethicon Endo-Surgery Vascular Access' intravenous catheters to bolster its existing fluid and drug delivery systems
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.